334 related articles for article (PubMed ID: 24816865)
1. Prognostic importance of baseline and serial glycated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study.
Cardoso CR; Leite NC; Ferreira MT; Salles GF
Acta Diabetol; 2015 Feb; 52(1):21-9. PubMed ID: 24816865
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Importance of C-Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study.
Cardoso CR; Leite NC; Salles GF
J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912211
[TBL] [Abstract][Full Text] [Related]
3. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
Cardoso CRL; Leite NC; Moram CBM; Salles GF
Cardiovasc Diabetol; 2018 Feb; 17(1):33. PubMed ID: 29477146
[TBL] [Abstract][Full Text] [Related]
4. Associations of Glycemic Control With Cardiovascular Outcomes Among US Hemodialysis Patients With Diabetes Mellitus.
Rhee JJ; Zheng Y; Montez-Rath ME; Chang TI; Winkelmayer WC
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28592463
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus: A 10-year longitudinal cohort study.
Kim MK; Jeong JS; Yun JS; Kwon HS; Baek KH; Song KH; Ahn YB; Ko SH
J Diabetes Complications; 2018 Oct; 32(10):906-910. PubMed ID: 30121206
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Long-term HbA
Sheng CS; Tian J; Miao Y; Cheng Y; Yang Y; Reaven PD; Bloomgarden ZT; Ning G
Diabetes Care; 2020 Jun; 43(6):1185-1190. PubMed ID: 32229597
[TBL] [Abstract][Full Text] [Related]
7. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
[TBL] [Abstract][Full Text] [Related]
8. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
[TBL] [Abstract][Full Text] [Related]
9. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.
Ceriello A; Lucisano G; Prattichizzo F; La Grotta R; Franzén S; Svensson AM; Eliasson B; Nicolucci A
Cardiovasc Diabetol; 2022 Jan; 21(1):13. PubMed ID: 35073913
[TBL] [Abstract][Full Text] [Related]
10. Associations between usual glycated haemoglobin and cardiovascular disease in patients with type 2 diabetes mellitus: A 10-year diabetes cohort study.
Wan EY; Yu EY; Chen JY; Wong IC; Chan EW; Lam CL
Diabetes Obes Metab; 2020 Dec; 22(12):2325-2334. PubMed ID: 32744402
[TBL] [Abstract][Full Text] [Related]
11. The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease.
Bots SH; van der Graaf Y; Nathoe HM; de Borst GJ; Kappelle JL; Visseren FL; Westerink J;
Cardiovasc Diabetol; 2016 Jul; 15(1):101. PubMed ID: 27431507
[TBL] [Abstract][Full Text] [Related]
12. Visit-to-Visit Variability of Hemoglobin A
Ghouse J; Skov MW; Kanters JK; Lind B; Isaksen JL; Blanche P; Haunsø S; Køber L; Svendsen JH; Olesen MS; Holst AG; Gerds TA; Nielsen JB
Diabetes Care; 2019 Jan; 42(1):134-141. PubMed ID: 30352898
[TBL] [Abstract][Full Text] [Related]
13. Delta-glycated hemoglobin: a novel independent risk factor for cardiovascular events in patients without diabetes mellitus.
Diedrichs H; Pfister R; Clement Z; Hagemeister J; Schneider CA
J Endocrinol Invest; 2009 Jul; 32(7):564-7. PubMed ID: 19535894
[TBL] [Abstract][Full Text] [Related]
14. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).
Eeg-Olofsson K; Cederholm J; Nilsson PM; Zethelius B; Svensson AM; Gudbjörnsdóttir S; Eliasson B
J Intern Med; 2010 Nov; 268(5):471-82. PubMed ID: 20804517
[TBL] [Abstract][Full Text] [Related]
15. Association of glycated hemoglobin A
Sinning C; Makarova N; Völzke H; Schnabel RB; Ojeda F; Dörr M; Felix SB; Koenig W; Peters A; Rathmann W; Schöttker B; Brenner H; Veronesi G; Cesana G; Brambilla P; Palosaari T; Kuulasmaa K; Njølstad I; Mathiesen EB; Wilsgaard T; Blankenberg S; Söderberg S; Ferrario MM; Thorand B
Cardiovasc Diabetol; 2021 Nov; 20(1):223. PubMed ID: 34781939
[TBL] [Abstract][Full Text] [Related]
16. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
[TBL] [Abstract][Full Text] [Related]
17. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.
Östgren CJ; Sundström J; Svennblad B; Lohm L; Nilsson PM; Johansson G
Diabet Med; 2013 May; 30(5):e170-7. PubMed ID: 23350893
[TBL] [Abstract][Full Text] [Related]
18. Age-specific associations of glycated haemoglobin variability with cardiovascular disease and mortality in patients with type 2 diabetes mellitus: A 10- year cohort study.
Wan EYF; Yu EYT; Chin WY; Ng FTY; Chia SMC; Wong ICK; Chan EWY; Lam CLK
Diabetes Obes Metab; 2020 Aug; 22(8):1316-1327. PubMed ID: 32196917
[TBL] [Abstract][Full Text] [Related]
19. Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease.
Rezende PC; Hlatky MA; Hueb W; Garcia RMR; da Silva Selistre L; Lima EG; Garzillo CL; Scudeler TL; Boros GAB; Ribas FF; Serrano CV; Ramires JAF; Kalil Filho R
JAMA Netw Open; 2020 Jan; 3(1):e1919666. PubMed ID: 31968117
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study.
Zhang Y; Jin JL; Cao YX; Zhang HW; Guo YL; Wu NQ; Zhu CG; Gao Y; Hua Q; Li YF; Xu RX; Li JJ
Cardiovasc Diabetol; 2020 Jul; 19(1):111. PubMed ID: 32646432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
